ERBB2 and metastatic neoplasm: This is especially significant considering that overall HER2-positive cases and 30–50% of triple-negative patients (in the context of HER2-low disease) could undergo an ADC sequence during their treatment for metastatic disease, thanks to regulatory agency approvals.